![The proportion of end-of-dose failure on visit 1 and visit 2. After the... | Download Scientific Diagram The proportion of end-of-dose failure on visit 1 and visit 2. After the... | Download Scientific Diagram](https://www.researchgate.net/publication/259878880/figure/fig3/AS:202657848401948@1425328804922/The-proportion-of-end-of-dose-failure-on-visit-1-and-visit-2-After-the-use-of-fentanyl.png)
The proportion of end-of-dose failure on visit 1 and visit 2. After the... | Download Scientific Diagram
![Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease | Neurology Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease | Neurology](https://n.neurology.org/content/neurology/89/7/e83/F1.large.jpg)
Teaching Video NeuroImages: The underrecognized diphasic dyskinesia of Parkinson disease | Neurology
![Treatment Strategies to Overcome End-of-Dose Failure With Oral and Transdermal Opioids | Semantic Scholar Treatment Strategies to Overcome End-of-Dose Failure With Oral and Transdermal Opioids | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/4dda2089df33837e992a8b247ad842dfe43f8a46/3-Table1-1.png)
Treatment Strategies to Overcome End-of-Dose Failure With Oral and Transdermal Opioids | Semantic Scholar
![Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF Periods | Neurology and Therapy Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF Periods | Neurology and Therapy](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs40120-023-00486-5/MediaObjects/40120_2023_486_Fig1_HTML.png)
Clinical Use of On-Demand Therapies for Patients with Parkinson's Disease and OFF Periods | Neurology and Therapy
![End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease | SpringerLink End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs00415-006-0320-z/MediaObjects/415_2006_320_f1.jpg)
End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease | SpringerLink
![Levodopa-Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease: The Role of COMT Inhibitors Levodopa-Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease: The Role of COMT Inhibitors](https://img.medscapestatic.com/slide/migrated/editorial/cmecircle/2004/3402/images/melamed/slide011.gif)
Levodopa-Continuous Dopaminergic Stimulation in the Treatment of Parkinson's Disease: The Role of COMT Inhibitors
Fluctuation of arterial blood pressure during end-of-dose akinesia in Parkinson's disease. - Abstract - Europe PMC
![Sensors | Free Full-Text | Technologies for Assessment of Motor Disorders in Parkinson's Disease: A Review Sensors | Free Full-Text | Technologies for Assessment of Motor Disorders in Parkinson's Disease: A Review](https://www.mdpi.com/sensors/sensors-15-21710/article_deploy/html/images/sensors-15-21710-g001.png)